Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
This trial is active, not recruiting.
|Start date||February 2014|
|End date||January 2016|
|Trial size||10 participants|
|Trial identifier||NCT01635712, SNX-5422-CLN1-005|
Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Sacramento, CA||University of California Davis Comprehensive Cancer Center||no longer recruiting|
|Augusta, GA||Georgia Regents University Cancer Center||no longer recruiting|
|Hackensack, NJ||Hackensack University Medical Center||no longer recruiting|
|Winston-Salem, NC||Wake Forest Baptist Health||no longer recruiting|
|Winston-Salem, NC||Wake Forest University Health Sciences||no longer recruiting|
|Nashville, TN||Vanderbilt-Ingram Cancer Center||no longer recruiting|
|Nashville, TN||Vanderbilt University / Ingram Cancer Center||completed|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
Number of patients with dose limiting toxicities
time frame: First 28 day cycle
Number of patients with adverse events as a measure of tolerability
time frame: Day 28 of each cycle
time frame: Completion of every two 28 day cycles
Male or female participants at least 18 years old.
- Males or non-pregnant, non-breastfeeding females 18 years-of-age or older with histologically confirmed non-Hodgkins lymphoma, without known or clinically suspected CNS involvement, that is refractory to available therapy or for which there is no available therapy.
- No more than 4 prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within 12 months of dosing, and no prior allogeneic transplant.
- Karnofsky performance score ≥60
- Life expectancy of at least 3 months.
- Adequate baseline laboratory assessments
- Currently receiving anticancer therapy or have received anticancer therapy within the past 28 days or 5 half-lives of the anticancer therapy
- The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422
- At increased risk for developing prolonged QT interval, including hypokalemia or hypomagnesemia, unless corrected to within normal limits prior to first dose of SNX-• Chronic diarrhea.
- Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
- Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
- History of documented adrenal dysfunction not due to malignancy.
- Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV).
- History of chronic liver disease
|Official title||A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies|
|Description||SNX-5422 is a prodrug for SNX-2112. Correlation has been observed between Hsp90 client protein level changes and functional effects in cells in in vitro studies of SNX-2112, supporting inhibition of Hsp90 as the mechanism of action for this compound. SNX-5422 has demonstrated significant antitumor activity in mouse xenograft models of human tumors, including breast (BT474, MX-1), colon (HT29), prostate (PC3), and melanoma (A375) with multiple oral dosing regimens. Pharmacokinetic (PK) studies in mice, rats, and dogs have shown high bioavailability of SNX-2112 following oral administration of SNX 5422. In mouse xenograft studies, SNX-2112 was selectively retained in tumor tissue compared with other tissues. This study will employ critical risk management features including the use of the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, which provides a scale for consistently grading the severity of AEs, toxicity criteria analyses for dose escalation, frequent laboratory and clinical observations, correlation of AEs with plasma concentrations of SNX-5422 and SNX-2112, monitoring of the QTc interval at appropriate time points, and a conservative dose-escalation scheme.|
Call for more information